It's no secret that pharma companies are struggling to protect themselves from cyberattacks amid the pandemic. Data breaches are costing the sector around US$5m a year, while one in 10 pharma companies are at risk of a ransomware attack, exacerbated by a perfect storm of shifting to remote working, increased growth, antiquated OT systems and a lack of cybersecurity skills.
Watch Now
Digitalization in the pharmaceutical industry is a pervasive and persistent phenomenon that rapidly changes how patients engage with pharma and purchase drugs. The pandemic has just accelerated the changes which already began before
Watch Now
Despite the efforts towards malaria eradication, the latest estimates show that the number of cases is rising and malaria continues to have a devastating impact on the most vulnerable populations.
Watch Now
ICAGEN, INC
Innovation continues to be a primary driver of value in pharmaceutical research. However, simultaneously, research budgets are coming under ever-increasing pressure. As a consequence, pharma is moving toward a so-called open research model, one that dispenses with recurrent fixed costs in favor of a more flexible and dynamic external “spend.” By adopting this model, pharma could tap into innovation outside their walls. In this webinar, case studies will be presented highlighting the value of such collaborations, while focusing on discovery campaigns that employ highly relevant functional assays.
Watch Now